ACD856 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: neurotrophin signaling and cognitive dysfunction

Nootropic Compounds compound PowderLiquid needs_revision Best effort · source review pending

Also known as: ACD-856

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

10 mg/mL solution, Custom laboratory pack

Storage

Supplier-listed solid storage is -20 deg C; solution stability is formulation-specific and should follow the study protocol or COA

Solubility

Laboratory suppliers report 10 mM solubility in DMSO; the sponsor's clinical oral solution is formulation-specific

Best-Effort Research Profile

ACD856 is an investigational small-molecule positive allosteric modulator of Trk receptors. Published work reports preclinical neurotrophic and cognition findings, while the available human evidence is limited to early clinical development and does not establish efficacy.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Mean terminal half-life 19.4 hours after a 0.1 mg IV microdose; oral values were dose-dependent in Phase 1

Onset

Human efficacy onset is not established; Phase 1 assessed pharmacokinetics and pharmacodynamic signals rather than clinical benefit

Administration Routes (Research)

OralIntravenous (IV)

Reported Research Effects

Pan-Trk positive allosteric modulation
Enhanced neurotrophin signaling in preclinical models
Phase 1 human safety and pharmacokinetics published
Phase Ib positive safety and pharmacodynamic results reported by sponsor in 2026; peer-reviewed efficacy evidence is not yet available

Reported Research Side Effects

Investigational - full human safety profile not yet publicly established beyond Phase 1
No long-term human safety data published

Data source: Peer-reviewed primary research and early clinical-development records

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established

Oral Human study only

1-150 mg single oral doses

Frequency / timing: Study day 1
Duration / setting: Single dose
Technique: Oral
Evidence: Human study protocol

Context: published Phase 1 healthy-volunteer study

Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Source 1

Intravenous (IV) Human study only

0.1 mg microdose

Frequency / timing: Study day 1
Duration / setting: Single dose
Technique: IV
Evidence: Human study protocol

Context: published Phase 0 pharmacokinetic study

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Source 1

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Sources Under Review

ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics — PubMed Central (NIH)
https://pmc.ncbi.nlm.nih.gov/articles/PMC11001683/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.